American Association for the Study of Liver Disease and Infectious Diseases Society of America website. Recommendations for testing, managing and treating hepatitis C. http://www.hcvguidelines.org/. Accessed January 1, 2017.
Department of Health and Human Services. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed January 2, 2017.
Macias J, Berenguer J, Japon MA, et al. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology. 2009;50:1056-1063. Abstract
Konerman MA, Mehta SH, Sutcliffe CG, et al. Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs. Hepatology. 2014;59:767-775. Abstract
Kirk GD, Mehta SH, Astemborski J, et al. HIV, age, and the severity of hepatitis C virus-related liver disease: a cohort study. Ann Intern Med. 2013;158:658-666. Abstract
Descovey® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2016.
Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-e327. Abstract
Zeuzem S, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: A randomized trial. Ann Intern Med. 2015;163:1-13. Abstract
Osinusi A, Townsend K, Kohli A, et al. Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infection. JAMA. 2015;313:1232-1239. Abstract
Naggie S, Cooper C, Saag M, et al. Ledipasvir and sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015;373:705-713. Abstract
Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015; 385:1087-1097. Abstract
Wyles DL, Ruane PJ, Sulkowski MS, et al Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1. N Engl J Med. 2015, 20;373:714-725.
Sulkowski MS, Eron JJ, Wyles D, et al. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: A randomized trial. JAMA. 2015; 313:1223-1231. Abstract
Wyles D, Brau N, Kottilil S et al. Sofosbuvir/velpatasvir fixed dose combination for 12 weeks in patients co-infected with HCV and HIV-1. Abstract presented at: The International Liver Congress 2016; April 13-17, 2016; Barcelona, Spain. Abstract PS104.
Harvoni® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2016.
Daklinza™ [package insert]. Princeton, NJ: Bristol-Myers Squibb Company. 2016.
Zepatier™ [package insert]. Whitehouse Station, NJ: Merck & Co., Inc. 2016.
Olysio® [package insert]. Titusville NJ; Janssen Therapeutics. 2016
Solvadi® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2015.
Epclusa® [package insert]. Foster City, CA: Gilead Sciences, Inc. 2016.
Viekira Pak™, Viekira XR™ [package insert]. North Chicago, Il: AbbVie Inc. 2016.
Technivie™ [package insert]. North Chicago, Il: AbbVie Inc. 2016
Copegus® [package insert]. South San Francisco, CA: Genentech USA, Inc. 2011.
Manns MP, Pockros PJ, Norkrans G, et al. Long-term clearance of hepatitis C virus following interferon alpha-2b or peginterferon alpha-2b, alone or in combination with ribavirin. J Viral Hepat. 2013;20:524-529. Abstract
Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022. Abstract
George SL, Bacon BR, Brunt EM, et al. Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology. 2009;49:729-738. Abstract
Morgan TR, Ghany MG, Kim HY, et al. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010;52:833-844. Abstract
Singal AG, Volk ML, Jensen D, et al. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010;8:280-288. Abstract
Morisco F, Granata R, Stroffolini T, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol. 2013;19:2793-2798. Abstract
Morgan RL, Baack B, Smith BD, et al. Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies. Ann Intern Med. 2013;158:329-337. Abstract
Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817-826. Abstract
van der Meer AJ, Berenguer M. Reversion of disease manifestations after HCV eradication. J Hepatol. 2016;65:S95-S108. Abstract
Hsu YC, Lin JT, Ho HJ, et al. Antiviral treatment for hepatitis C virus infection is associated with improved renal and cardiovascular outcomes in diabetic patients. Hepatology. 2014;59:1293-1302. Abstract
Roth D, Nelson DR, Bruchfeld A et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet. 2015;386:1537-1545. Abstract
Lawitz E, Flamm S, Yang JC, et al. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir-based regimens with ledipasvir/sofosbuvir for 24 weeks. Abstract presented at: The 50th Annual Meeting of the European Association for the Study of the Liver (EASL); April 22-26, 2015; Vienna, Austria. Abstract 0005.
Lawitz E, Matusow G, DeJesus E, et al. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A Phase 3 study (OPTIMIST-2). Hepatology. 2015;64:360-369.
Kwo P, Gane E, Peng C-Y, et al. P0886: efficacy and safety of grazoprevir/elbasvir +/- RBV for 12 weeks in patients with HCV G1 or G4 infection who previously failed peginterferon/RBV: C-edge treatment-experienced trial. J Hepatol. 2015;62:S674-S675.
Collins JM, Raphael KL, Terry C, et al. Hepatitis B virus reactivation during successful treatment of hepatitis C virus with sofosbuvir and simeprevir. Clin Infect Dis. 2015;61:1304-1306. Abstract
De Monte A, Coujon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27-30. Abstract
Ende AR, Kim NH, Yeh MM, et al. Fulminant hepatitis B reactivation leading to liver transplantation in a patient with chronic hepatitis C treated with simeprevir and sofosbuvir: a case report. J Med Case Rep. 2015;9:164.
Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct acting antiviral agents. Clin Gastroenterol Hepatol. 2017;15:132-136. Abstract
US Food and Drug Administration website. FDA Drug Safety Communication: FDA warns about the risk of hepatitis B reactivating in some patients treated with direct-acting antivirals for hepatitis C. http://www.fda.gov/Drugs/DrugSafety/ucm522932.htm. Accessed January 2, 2017.

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Faculty

Jordan Feld, MD, MPH

Associate Professor of Medicine, University of Toronto, Ontario, Canada

Disclosures

Disclosure: Jordan Feld, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.
Received grants for clinical research from: Abbott Laboratories; AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Regulus Pharmaceutical Consulting, Inc.

Dr Feld does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Feld does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Charles Howe, PharmD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charles Howe, PharmD, has disclosed he
Owns stock in GlaxoSmithKline

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

CME / ABIM MOC / CE

One Size Does Not Fit All: Personalizing Care in HCV

Authors: Jordan Feld, MD, MPH
CME / ABIM MOC / CE Released: 2/24/2017
THIS ACTIVITY HAS EXPIRED FOR CREDIT
Valid for credit through: 2/24/2018, 11:59 PM EST

Start Activity

Target Audience and Goal Statement

This activity is intended for gastroenterologists, primary care physicians, ID/HIV specialists, and nurses.

The goal of this activity is to improve clinicians ability to treat hepatitis C virus (HCV) infection in patients with stage 4/5 chronic kidney disease and human immunodeficiency virus (HIV) infection, and identify appropriate use of elbasvir/grazoprevir.

Upon completion of this activity, participants will:

have increased knowledge regarding the:
1. Key safety and efficacy data for emerging/newer HCV antivirals
have greater competence related to:
1. Appropriately incorporating newer HCV antiviral agents into clinical practice in the context of severe renal impairment
2. Appropriately incorporating newer HCV antiviral agents into clinical practice in the context of HIV coinfection

Disclosures

Faculty

Jordan Feld, MD, MPH

Associate Professor of Medicine, University of Toronto, Ontario, Canada

Disclosures

Disclosure: Jordan Feld, MD, MPH, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: AbbVie Inc.; Bristol-Myers Squibb Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.
Received grants for clinical research from: Abbott Laboratories; AbbVie Inc.; Gilead Sciences, Inc.; Janssen Pharmaceuticals; Merck & Co., Inc.; Regulus Pharmaceutical Consulting, Inc.

Dr Feld does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

Dr Feld does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

Charles Howe, PharmD

Scientific Director, Medscape, LLC

Disclosures

Disclosure: Charles Howe, PharmD, has disclosed he
Owns stock in GlaxoSmithKline

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Lead Nurse Planner, Medscape, LLC

Disclosures

Disclosure: Amy Bernard, MS, BSN, RN-BC, has disclosed no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has disclosed no relevant financial relationships.

Accreditation Statements

Medscape, LLC is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Medscape, LLC staff have disclosed that they have no relevant financial relationships.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.00 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.50 contact hours are in the area of pharmacology.

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read the target audience, learning objectives, and author disclosures.
Study the educational content online or printed out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

processing....

Abbreviations

AASLD = American Association for the Study of Liver Diseases
AIDS = acquired immune deficiency syndrome
ALT = alanine transaminase
anti-HAV = hepatitis A virus antibody
ART = antiretroviral therapy
AST = aspartate transaminase
BMI = body mass index
BP = blood pressure
bpm = beats per minute
CBC = complete blood count
cGFR = calculated glomerular filtration rate
CrCl = estimated creatinine clearance
CTP = Child-Turcotte-Pugh
DAA = direct-acting antiviral
DCV = daclatasvir
eGRF = estimated glomerular filtration rate
EBR = elbasvir
EGD = esophagogastroduodenoscopy
ELISA = enzyme-linked immunosorbent assay
ESRD = end-stage renal disease
FDA = US Food and Drug Administration
FTC = emtricitabine
GERD = gastroesophageal reflux disease
GT = genotype
GZR = grazoprevir
HAV = hepatitis A virus
HBsAg = hepatitis B surface antigen
HBV = hepatitis B virus
HCC = hepatocellular carcinoma
HCV = hepatitis C virus
HD = hemodialysis
HDLc = high-density lipoprotein cholesterol
Hgb = hemoglobin
HIV = human immunodeficiency virus
GERD = gastroesophageal reflux disease
HR = heart rate
IDSA = Infectious Diseases Society of America
INR = international normalized ratio
kPa = kilopascal
LDLc = low-density lipoprotein cholesterol
LDV = ledipasvir
NS5A = nonstructural protein 5A
PEG-IFN = pegylated interferon
PrOD = paritaprevir/ritonavir/ombitasvir + dasabuvir
RAS = resistance-associated substitution
RAV = resistance-associated variant
RBV = ribavirin
RR = respiratory rate
SMV = simeprevir
SOF = sofosbuvir
TDF = tenofovir disoproxil fumarate
TDF/FTC = tenofovir disoproxil fumarate/emtricitabine
TDF = tenofovir
VEL = velpatasvir
WBC = white blood cell
WNL = within normal limits

« Return to: One Size Does Not Fit All: Personalizing Care in HCV

CME / ABIM MOC / CE Information

Print
Like Tweet

References

Faculty and Disclosures

Faculty

Jordan Feld, MD, MPH

Editor

Charles Howe, PharmD

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

CME / ABIM MOC / CE

One Size Does Not Fit All: Personalizing Care in HCV

Target Audience and Goal Statement

Disclosures

Faculty

Jordan Feld, MD, MPH

Editor

Charles Howe, PharmD

CME Reviewer / Nurse Planner

Amy Bernard, MS, BSN, RN-BC

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

Instructions for Participation and Credit

One Size Does Not Fit All: Personalizing Care in HCV

Abbreviations